World · India Bureau
Two Indian nationals charged for distributing counterfeit Ozempic in US
US authorities have charged two Indian nationals with operating a scheme to sell fake versions of the popular diabetes and weight-loss medication Ozempic, sourced from China. The illicit operation continued even after regulatory warnings and FDA seizures of counterfeit products.
LSN India ·
Two Indian nationals have been charged in the United States for their involvement in a scheme to distribute counterfeit Ozempic, the in-demand diabetes and weight-loss medication manufactured by Novo Nordisk. The defendants allegedly sourced the fake pharmaceutical products from China and distributed them to unsuspecting consumers across the US market.
The fraudulent operation demonstrated persistence despite increased regulatory scrutiny. In December 2023, the US Food and Drug Administration seized counterfeit Ozempic products and issued a public warning alerting consumers to the dangers of counterfeit versions. Despite this enforcement action, the scheme reportedly continued operating.
Counterfeit medications pose significant health risks to consumers, as they may contain incorrect dosages, harmful substances, or no active ingredients. The widespread demand for Ozempic—driven by its effectiveness in managing type 2 diabetes and its off-label use for weight management—has created a lucrative market for counterfeiters globally.
The charges represent ongoing efforts by US law enforcement and regulatory agencies to combat pharmaceutical fraud and protect public health. Authorities continue to warn consumers to obtain medications only through licensed pharmacies and healthcare providers, and to verify the authenticity of prescription drugs through official channels.